- Direct Fluorescent Tests
- Nucleic Acid Amplification Tests
Chlamydia Infection Diagnostics And Therapeutics Market size was valued at USD 2.6 billion in 2022 and is poised to grow at a CAGR of 6.1% from 2023-2029. Chlamydia is a sexually transmitted disease (STD) caused by the bacteria Chlamydia trachomatis, and it can be transmitted to a baby at birth. chlamydia infection diagnostics and therapeutics market usually does have any symptoms but often infected may have symptoms such as genital pain and genital discharge both in men and women. Furthermore, chlamydia infection can cause health complications such as preventing women from getting pregnant or even endangering their pregnancies. Some people may experience pain in the lower abdomen, pelvis, testicle, or vagina and may also have eye discharge or spotting. Treatment may include antibiotics and anti-inflammatory agents, and a hospital stay may be required. The global chlamydia infection diagnostics and therapeutics market is growing at significant rates owing to the prevalence rate of sexually transmitted diseases. According to the World Health Organization (WHO), worldwide, more than one million sexually transmitted infections are acquired every day. Each year, an estimated of 131 million new cases of chlamydia infection are reported. Companies are focusing on the development of new ways to detect chlamydia infection in the initial stages. For instance, in December 2016, F. Hoffmann-La Roche AG launched Cobas 6800/8800 systems for the detection of Chlamydia trachomatis and Neisseria Gonorrhoea (NG) DNA.
Fastest Growing Market
Global chlamydia infection diagnostics and therapeutics market is mainly driven by an increase in prevalence of sexually transmitted diseases worldwide. Furthermore, emergence of rapid test and advances in biotechnology are expected to boost the chlamydia infection diagnostics and therapeutics market. In addition, increase in R&D activities towards development of therapeutics for antibiotic-resistant bacteria and initiatives by government and non-government agencies (such as World Health Organization (WHO) to increase awareness about STD and their symptoms are expected to bolster the chlamydia diagnostics and therapeutics market during the forecast period. However, high cost of development, stringent regulatory procedures for the approval and bacterial drug resistance is expected to hamper the chlamydia infection diagnostics and therapeutics market.
The chlamydia infection diagnostics and therapeutics market is projected to expand at a CAGR of 6.1% during the forecast period
Abbott Laboratories, Bio-Rad Laboratories Inc, Becton Dickinson and Company, bioMérieux, DiaSorin SpA
North America is the fastest-growing region for chlamydia infection diagnostics and therapeutics market